Oncology specialists from around the globe will gather for the American Society of Clinical Oncology (ASCO) Annual Meeting to discuss the latest cancer therapies, technologies, research and education. The theme this year is Partnering With Patients: The Cornerstone of Cancer Care and Research. More than 30,000 people are expected to attend the meeting taking place in Chicago and online June 2-6, 2023.
The accuracy of prostate-specific antigen (PSA) screening for prostate cancer can be improved by accounting for genetic factors that cause changes in PSA levels that are not associated with cancer, according to a multi-center study led by UC San Francisco and Stanford University.
Alan Ashworth, PhD, FRS, president of the UCSF Helen Diller Family Comprehensive Cancer Center and senior vice president for cancer services at UCSF Health, has received two prestigious national awards for his transformative research accomplishments and work developing PARP inhibitors for cancer.
UCSF Health hospitals at Mission Bay and Parnassus Heights earned an “A” Hospital Safety Grade from The Leapfrog Group for spring 2023 – a national recognition of excellence for protecting patients from preventable harm and errors.
Beginning May 9, UC San Francisco will be the first hospital in California, and one of only a few nationwide, to offer pharmacogenetic testing. The test will provide critical clues about a patient’s unique genetic makeup, enabling pharmacists to tailor medications and dosages accordingly.
UCSF Health’s surgical oncology team is a Bay Area leader in an innovative chemotherapy infusion pump used to treat patients with widely metastatic colorectal and bile duct cancers that have spread to the liver and are no longer considered operable.
Earlier this year, Roxanna Bautista and Lisa Tealer were appointed co-leaders of the Cancer Center’s Community Advisory Board (CAB). In this Q & A, Bautista and Tealer discuss their community advocacy work and the CAB’s important role as a partner to the Cancer Center.
Funded by various agencies across UCSF, the awards span a range of topics from targeting cell growth in pancreatic cancer to predicting head and neck radiotherapy toxicities to evaluating a digital health intervention in breast cancer patients.
Drs. Anil Bidkar, Robert Flavell, and Bin Liu along with other co-authors have recently published a paper on a therapeutic strategy to address the limitations of current PSMA-directed theranostic agents for prostate cancer.
Cancer treatment routinely involves taking out lymph nodes near the tumor in case they contain metastatic cancer cells. But new findings from a clinical trial by researchers at UC San Francisco and Gladstone Institutes shows that immunotherapy can activate tumor-fighting T cells in nearby lymph nodes.